NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55566-8403-01 | 55566-8403 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | In Use | |||
55566-8301-00 | 55566-8301 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | March 31, 2015 | No Longer Used | ||
55566-8301-01 | 55566-8301 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | March 31, 2015 | No Longer Used | ||
55566-8301-02 | 55566-8301 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | May 24, 2013 | March 31, 2015 | No Longer Used | ||
55566-8401-00 | 55566-8401 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | March 31, 2015 | No Longer Used | ||
55566-8401-01 | 55566-8401 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | March 31, 2015 | No Longer Used | ||
55566-8401-02 | 55566-8401 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | May 24, 2013 | March 31, 2015 | No Longer Used | ||
57894-0469-01 | 57894-0469 | Talquetamab | TALVEY | 3.0 mg/1.5mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug. 9, 2023 | In Use | |
57894-0470-01 | 57894-0470 | Talquetamab | TALVEY | 40.0 mg/mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug. 9, 2023 | In Use | |
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov. 25, 2020 | In Use | |
66302-0014-01 | 66302-0014 | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | Intravenous | March 10, 2015 | In Use | |
62856-0389-01 | 62856-0389 | Eribulin mesylate | Halaven | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Nov. 15, 2010 | In Use | |
71335-1772-01 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
71335-1772-02 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
71335-1772-03 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
71335-1772-04 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
71335-1772-05 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
71335-1772-06 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Jan. 21, 2021 | In Use | |
71335-1772-07 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
71335-1772-08 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2021 | In Use | |
61703-0350-09 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | Sept. 25, 2014 | In Use | |
61703-0350-10 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | Sept. 25, 2014 | In Use | |
61703-0350-37 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | July 27, 2005 | In Use | |
61703-0350-38 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | July 27, 2005 | In Use | |
61703-0408-22 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Feb. 26, 2001 | Nov. 2, 2011 | In Use |
Found 10,000 results in 6 milliseconds — Export these results